ScripViking Therapeutics is continuing to advance dual GLP-1/GIP receptor agonist VK2735 on two tracks for obesity, with a pair of Phase III trials of the weekly injectable formulation under way, while a P
ScripRoche CEO Thomas Schinecker has added his voice to criticism of the middle men in the US biopharma sector, such as pharmacy benefit managers who negotiate discounts and rebates in exchange for reimbur
ScripRoche, Sarepta Therapeutics’ ex-US partner for the commercialization of Elevidys (delandistrogene moxeparvovec), has voluntarily and temporarily paused shipments of the Duchenne muscular dystrophy (DM
ScripRoche’s recent Phase III failure for its anti-ST2 monoclonal antibody, astegolimab, in chronic obstructive pulmonary disease (COPD) is a blow not just for the firm but also for the fledgling drug clas